EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

RNA Therapeutics for Duchenne Muscular Dystrophy: Exon Skipping, RNA Editing, and Translational Insights from Genome-Edited Microminipig Models

Alex Chassin, Hiroya Ono iD, Yuki Ashida, Michihiro Imamura, Yoshitsugu Aoki iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27062755 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Alex Chassin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Therapy, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, Tokyo 187-8502, Japan. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Exons, RNA Editing, Genetic Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid from the Japan Society for the Promotion of Science (JSPS) KAKENHI, National Center of Neurology and Psychiatry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disease (NMD) caused by loss-of-function mutations in the DMD gene. RNA-based therapies, especially antisense oligonucleotides (ASO)-mediated exon skipping and adenosine deaminase acting on RNA (ADAR)-guided RNA editing, have emerged as complementary approaches that modulate pre-mRNA splicing or correct transcripts without altering genomic DNA. Current phosphorodiamidate morpholino oligomer (PMO) drugs targeting exons 51, 53, and 45 provide mutation-class-specific benefit. At the same time, next-generation delivery strategies (e.g., peptide-conjugated PMOs (PPMOs), antibody–oligonucleotide conjugates (AOC), and endosomal-escape vehicles) aim to improve skeletal, cardiac, and diaphragm exposure. In parallel, RNA editing strategies offer a route to correct select nonsense or missense variants at the base level and may, in principle, restore near-native dystrophin expression. Meaningful translation of these modalities requires predictive large-animal models. A genome-edited microminipig (MMP) bearing DMD exon-23 mutations faithfully recapitulates hallmark features of human DMD. That includes early locomotor deficits, elevated serum creatine kinase (CK) and cardiac troponin T, progressive myocardial fibrosis, and a decline in left-ventricular ejection fraction (LVEF), while maintaining a manageable lifespan of approximately 30 months suitable for long-term studies. In particular, the MMP model provides a practical platform for addressing the persistent challenge of efficient therapeutic delivery to the heart and diaphragm through longitudinal dosing, imaging, and biopsy. In this review, we synthesize clinical progress in exon skipping, outline the promise of RNA editing, and integrate recent insights from Duchenne muscular dystrophy model for microminipigs (DMD-MMPs) as an advanced surrogate for preclinical development and translational evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneExonsRNA EditingGenetic TherapyHumansAnimalsOligonucleotides, AntisenseDisease Models, AnimalDystrophin

Stichwörter der Autor:innen

ADARDuchenne muscular dystrophyRNA editingRNA therapeuticsanimal modelsantibody–oligonucleotide conjugateantisense oligonucleotidesexon skippinggenome editingmicrominipigpeptide-conjugated PMOphosphorodiamidate morpholino oligomer

Substanzen

Oligonucleotides, AntisenseDystrophin

Autor:innen und Institutionen

  • Department of Molecular Therapy, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, Tokyo 187-8502, Japan.
  • Tissular, Cellular and Gene Biotherapy, Université Paris-Saclay, 91190 Gif-sur-Yvette, France.

ORCID-Profile: Hiroya Ono, Yoshitsugu Aoki

Förderung

  • Grant-in-Aid from the Japan Society for the Promotion of Science (JSPS) KAKENHI
  • National Center of Neurology and Psychiatry

Zitieren

APA

Chassin, A., Ono, H., Ashida, Y., Imamura, M., & Aoki, Y. (2026). RNA Therapeutics for Duchenne Muscular Dystrophy: Exon Skipping, RNA Editing, and Translational Insights from Genome-Edited Microminipig Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062755

Vancouver

Chassin A, Ono H, Ashida Y, Imamura M, Aoki Y. RNA Therapeutics for Duchenne Muscular Dystrophy: Exon Skipping, RNA Editing, and Translational Insights from Genome-Edited Microminipig Models. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062755

BibTeX
@article{Chassin2026,
  author = {Chassin, Alex and Ono, Hiroya and Ashida, Yuki and Imamura, Michihiro and Aoki, Yoshitsugu},
  title = {RNA Therapeutics for Duchenne Muscular Dystrophy: Exon Skipping, RNA Editing, and Translational Insights from Genome-Edited Microminipig Models},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27062755}
}
Kostenlos starten →